1. Home
  2. VRTX vs BMY Comparison

VRTX vs BMY Comparison

Compare VRTX & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

N/A

Current Price

$517.10

Market Cap

135.6B

Sector

Technology

ML Signal

N/A

Logo Bristol-Myers Squibb Company

BMY

Bristol-Myers Squibb Company

N/A

Current Price

$59.02

Market Cap

127.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VRTX
BMY
Founded
1989
1887
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.6B
127.0B
IPO Year
2007
2006

Fundamental Metrics

Financial Performance
Metric
VRTX
BMY
Price
$517.10
$59.02
Analyst Decision
Buy
Hold
Analyst Count
32
28
Target Price
★ $595.36
$65.25
AVG Volume (30 Days)
1.3M
★ 9.0M
Earning Date
11-02-2026
10-29-2026
Dividend Yield
N/A
★ 4.32%
EPS Growth
★ 836.54
178.46
EPS
★ 10.90
3.98
Revenue
$2,488,652,000.00
★ $48,194,000,000.00
Revenue This Year
$10.46
$4.23
Revenue Next Year
$10.53
N/A
P/E Ratio
$47.77
★ $14.66
Revenue Growth
★ 46.20
N/A
52 Week Low
$412.27
$47.58
52 Week High
$568.67
$68.64

Technical Indicators

Market Signals
Indicator
VRTX
BMY
Relative Strength Index (RSI) 41.75 39.40
Support Level $493.75 $55.66
Resistance Level $536.58 $60.93
Average True Range (ATR) 15.90 1.71
MACD -3.73 -0.46
Stochastic Oscillator 4.74 13.93

Price Performance

Historical Comparison
VRTX
BMY

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

About BMY Bristol-Myers Squibb Company

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Share on Social Networks: